Clinics and Practice
Treatment Trajectories and Symptom Burden in Overactive Bladder: Long-Term Follow-Up of a Prospective, Nonrandomized Cohort
By Adam Ostrowski, Magdalena Ostrowska, Filip Kowalski and 7 others.
Abstract
Background
Long-term overactive bladder (OAB) care involves treatment changes that are not captured by initial-prescription persistence alone. We examined treatment pathways, symptom burden, and xerostomia.
Methods
This prospective nonrandomized cohort included 106 adults initially managed with solifenacin 5 mg, solifenacin 10 mg, or mirabegron 50 mg. Telephone interviews were completed by 83 participants after a mean of 32.6 months (range 29.8–35.3); 76 had reliable linked data, and 75 had current Overactive Bladder Symptom Score (OABSS). Treatment pathways, reasons for modification, and global patient-reported outcomes were described. Current antimuscarinic use and xerostomia were examined using exact testing and logistic regression.